louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01888029: Influence of tDCS on Cortical Plasticity in Patients With Mild Cognitive Impairment (MCI)
Official title: Influence of Transcranial Direct Current Stimulation on Cortical Plasticity in Patients With Mild Cognitive Impairment (MCI)
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Patients With Mild Cognitive Impairment
Keywords: mild cognitive impairment
Transcranial Direct Current Stimulation
Cortical Plasticity
Lead sponsor: Charite University, Berlin, Germany
Sponsor class: OTHER
First posted: 2013-06-27
Enrollment: 0
Sex: ALL
Minimum age (years): 50
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to investigate whether the anodal transcranial direct current stimulation (tDCS) over the primary motor cortex (M1) in patients with mild cognitive impairment (MCI) leads to an increase in cortical plasticity (change in motor evoked potentials (MEP) in mV).


Eligibility criteria: Inclusion Criteria:

* Right-handed according to the Oldfield Händigkeits inventory (lateralization index\> 70) (1971)
* Cognitive impairment according to the diagnostic criteria of a MCI (amnesic or even multiple domains)
* No therapeutic treatment with AChE inhibitors
* No motor impairments relevant to everyday life
* Age 50 to 80 years

Exclusion Criteria:

* Severe neurological / psychiatric or pre-existing internist conditions because additional cognitive deficits are expected
* Epilepsy, epileptic seizure in medical history
* Cognitive deficit (MMSE \<20)
* Depressive episode (Beck Depression Inventory (BDI)\> 12)
* Newly taking (\<3 months) centrally active drugs, particularly acetylcholinesterase inhibitors
* Pregnancy
* Pacemaker (contraindication for MRI)
* Other metal parts in the body (contraindication for MRI)

Primary outcomes:
measure: the anodal transcranial direct current stimulation over the primary motor cortex (M1) in patients with mild cognitive impairment (MCI)
timeFrame: 1 week
Secondary outcomes:
measure: Comparison of tDCS-induced changes on central cholinergic activity
timeFrame: 1 week
measure: Comparison of tDCS-induced changes in learning success
timeFrame: 1 week
measure: MR elastography
timeFrame: 1 week
measure: genetic polymorphism, ApoE4
timeFrame: once
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Klinik und Poliklinik für Neurologie, Charité Universitätsmedizin Berlin
Study officials:
References:
Clinical trial NCT06939829: A Multicenter Clinical Study on the Continuous vs. Intermittent Infusion of Ceftazidime-Avibactam in Critically Ill Patients With Severe Infections
Official title: A Prospective, Open-Label, Randomized Controlled, Multicenter Clinical Study on Continuous vs. Intermittent Infusion of Ceftazidime-Avibactam in Critically Ill Patients With Severe Infections
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE4
Conditions: Patients With Critically Ill Infections
Keywords: Ceftazidime-Avibactam
Continuous versus Intermittent Infusion
clinical study
Lead sponsor: Southeast University, China
Sponsor class: OTHER
First posted: 2025-04-23
Enrollment: 1200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective of this study is to determine whether continuous infusion of ceftazidime-avibactam (CAZ-AVI) could improve clinical outcomes in critically ill patients compared with intermittent infusion.

Detailed description: This study employs a prospective, open-label, randomized controlled, multicenter clinical trial design comparing "CAZ-AVI continuous infusion" versus "CAZ-AVI intermittent infusion," .The secondary objectives is to observe the clinical cure, Bacterial clearance, the probability of target attainment (PTA) of TDM. etc

Eligibility criteria: Inclusion Criteria:

* 18-85 years old, male or female.
* Patients who are admitted to ICU wards.
* Patients clinically diagnosed with carbapenem-resistant organism (CRO) infections, and has been commenced on targeted therapy with ceftazidime-avibactam.
* One or more organ dysfunction criteria in the previous 24 hours i. MAP \< 60 mmHg for at least 1 hour; ii. Vasopressors required for \> 4 hours; iii. Respiratory support using supplemental high flow nasal prongs, continuous positive airway pressure, bilevel positive airway pressure or invasive mechanical ventilation for at least 1 hour.

iv. Serum creatinine concentration \> 220 μmol/L or \>2.49 mg/dL

Exclusion Criteria:

* Patient has a known allergy to ceftazidime-avibactam.
* Patient has received ceftazidime-avibactam for more than 48 hours during current infectious episode.
* Patient is in severe condition or expected to survive for no more than 48 hours.
* Patient who receives lung or heart transplant or stem cell transplant.
* Patient is known or suspected to be pregnant.
* Patient has previously been enrolled in the current study.
* Other conditions which are regarded as inappropriate for enrollment.

Primary outcomes:
measure: 90-day all cause mortality
timeFrame: from randomization to day 90
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Department of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University
name: Feng jian Xie, MD
role: STUDY_CHAIR
References:
Clinical trial NCT00851929: Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension
Official title: Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Sarcoidosis
Pulmonary Hypertension
Keywords: sarcoidosis
pulmonary hypertension
dyspnea
sarcoidosis associated pulmonary hypertension
Lead sponsor: Medical University of South Carolina
Sponsor class: OTHER
Collaborators: name: Gilead Sciences
First posted: 2009-02-26
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Hypothesis: Ambrisentan (Letairis ®) is safe and effective in treating pulmonary hypertension in patients with Sarcoidosis

Detailed description: Primary Endpoint: Change in 6 minute walk distance.

Eligibility criteria: Inclusion Criteria:

* Biopsy proven sarcoidosis
* Mean pulmonary artery pressure \> 25 mmHg at rest and greater than 30 mmHg with exercise by right heart catheterization within 1 year prior to entry into study
* Pulmonary capillary wedge pressure ≤ 15 mmHg
* PVR values \>3.0 Woods units
* Forced vital capacity (FVC) \>40%
* WHO functional class II or III
* Stable sarcoidosis treatment regimen for three months prior to entry into study
* 6 minute walk distance between 150-450 meters
* Stable dose of antihypertensive medications
* On no other medication to treat PAH (sildenafil, tadalafil, vardenafil, treprostinil, epoprostenol, iloprost, bosentan, sitaxsentan) within one month prior to enrollment and during duration of the study
* Non-pregnant females

Exclusion Criteria:

* Exercise limitation related to a non-cardiopulmonary reason (e.g. arthritis)
* Severe systemic hypertension \> 170/95
* Patients with congestive heart failure (left ventricular dysfunction) or primary right ventricular dysfunction
* Anticipation by the investigator for escalation in sarcoidosis treatment during the course of the study
* Pulmonary hypertension related to etiology other than sarcoidosis (i.e. HIV, scleroderma, etc.)
* Use within 1 month of an endothelin receptor antagonists (bosentan, sitaxsentan).
* WHO functional class IV status
* Patients with significant left ventricular dysfunction
* Significant liver dysfunction not due to sarcoidosis.
* Patients with severe other organ disease felt by investigators to impact on survival during the course of the study.

Primary outcomes:
measure: Change in 6 minute walk distance.
timeFrame: 4 months of therapy
Secondary outcomes:
Other outcomes:
Locations:
city: Chapel Hill
country: United States
facility: University of North Carolina Medical Center
state: North Carolina
city: Charleston
country: United States
facility: Medical Univerrsity of South Carolina
state: South Carolina
Study officials:
affiliation: Medical University of South Carolina
name: Marc A Judson, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Medical University of South Carolina
name: Don C Rockey, MD
role: STUDY_CHAIR
References:
Clinical trial NCT05830929: Ovarian Tissue Cryopreservation and Subsequent Auto-Transplantation for Female Cancer Patients
Official title: Ovarian Tissue Cryopreservation and Subsequent Auto-Transplantation for Female Cancer Patients
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Neoplasms
Lead sponsor: Chinese University of Hong Kong
Sponsor class: OTHER
First posted: 2023-04-26
Enrollment: 100
Sex: FEMALE
Minimum age (years): 1
Maximum age (years): 35
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: Ovarian Tissue Cryopreservation will be provided to cancer patients to allow them to have their fertility preserved.

Detailed description: This project hopes to provide Ovarian Tissue Cryopreservation to patients who do not have adequate time for ovarian stimulation in oocyte or embryo freezing and in prepubertal girls where oocyte freezing is not possible. All the patients will have fertility preservation consultations with a fertility specialist in our unit to go through the details of ovarian Tissue Cryopreservation service and risks related to ovarian tissue cryopreservation procedures. After undergoing ovarian tissue collection via surgery, the collected ovarian tissue will be cryopreserved either by slow freezing or vitrification in our unit.

Eligibility criteria: Inclusion Criteria:

* Patients aged from 0-35 years old and diagnosed with cancer e.g., leukaemia, myeloproliferative or myelodysplastic diseases, lymphoma, bone tumours, neurological neoplasms and sarcoma, Paediatric bone marrow transplant patients
* Patients with any illness or who will undergo any type of treatment that may cause irreversible damage to their fertility, such as extensive abdominal surgery, high toxicity medication and treatments;
* Patients suffering from hormone-sensitive malignancies who will undergo medical treatment, such as radiotherapy and chemotherapy that is liable to damage their ovaries and deter them from conception in the future.

Exclusion Criteria:

* Patients with no anticipated oncologic therapies
* Patients who are pregnant
* Children with one ovary
* Children deemed high risk for perioperative complications
* Patients unable to provide consent/assent (i.e. significant psychiatric problems/cognitive delay)

Primary outcomes:
measure: Surgical complications
timeFrame: 15 years
Secondary outcomes:
measure: Pregnancy rate
timeFrame: 15 years
Other outcomes:
Locations:
city: Hong Kong
country: Hong Kong
facility: Prince of Wales Hospital
Study officials:
affiliation: Chinese University of Hong Kong
name: Jacqueline Pui Wah CHUNG, MBBS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05191329: Impact of Personality on Satisfaction Following Presbyopic Correction
Official title: Impact of Personality Type, Social Roles and Working Mandates οn Visual Capacity and Satisfaction of Patients That Underwent Pseudophakic Presbyopic Correction
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Personality
Patient Satisfaction
Presbyopia
Keywords: multifocal presbyopic correction
personality traits
vision oriented quality of life
Lead sponsor: Democritus University of Thrace
Sponsor class: OTHER
First posted: 2022-01-13
Enrollment: 120
Sex: ALL
Minimum age (years): 40
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: participants with presbyopia, either surgically or non surgically corrected, aged 40 to 85 years

Brief summary: Primary objective of this study is the exploration of the impact of personality type, social roles and working mandates οn the visual capacity and satisfaction of patients that underwent pseudophakic presbyopic correction.

Detailed description: Personality type, social types and working mandates will be evaluated as a routine procedure to patients that visit the Presbyopia Service of the University Hospital of Alexandroupolis, by means of structured questionnaires. Six months following pseudophakic presbyopic correction surgery, each study participant will be evaluated for his/her visual capacity and vision-specific quality of life. Regression modeling will be attempted in order to identify the exact demographics, social roles and personality type of the patient that is most compatible to receive pseudophakic presbyopic correction.

Eligibility criteria: Inclusion Criteria:

* presbyopia, patients of our outpatient ophthalmology clinic, age between 40 and 85 years

Exclusion Criteria:

* inability to cooperate, former diagnosis of mental disease

Primary outcomes:
measure: TPQue assessment
timeFrame: 6 months
measure: NEI-VFQ-25 assessment
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Alexandroupolis
country: Greece
facility: Department of Ophthalmology, University Hospital of Alexandroupolis
state: Evros
Study officials:
affiliation: Department of Ophthalmology, University Hospital of Alexandroupolis, Alexandroupolis, Greece
name: Georgios Labiris, MD,PhD
role: STUDY_CHAIR
References:
citation: Ntonti P, Bakirtzis M, Delibasis K, Seimenis I, Tsinopoulos I, Labiris G. Impact of personality on the decision process and on satisfaction rates in pseudophakic presbyopic correction. J Cataract Refract Surg. 2022 Dec 1;48(12):1433-1439. doi: 10.1097/j.jcrs.0000000000001021.
Clinical trial NCT01858129: Inhaled Corticosteroids for the Treatment of Transient Tachypnea of the Newborn
Official title: Inhaled Corticosteroids for the Treatment of Transient Tachypnea of the Newborn in Infants Born at >34 Weeks Gestation: A Prospective, Randomized, Double Blind, Placebo Controlled Study.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Transient Tachypnea of the Newborn
Keywords: TTN
Lead sponsor: Bnai Zion Medical Center
Sponsor class: OTHER_GOV
First posted: 2013-05-21
Enrollment: 56
Sex: ALL
Minimum age (years): 4
Maximum age (years): 6
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Transient Tachypnea of the Newborn (TTN) is a common respiratory disorder affecting late preterm and term babies caused by lung edema resulting from delayed absorption of fetal alveolar lung fluid.

The investigators hypothesize that ENAC expression will be up-regulated as a result of administration of corticosteroids. This effect will lead to enhanced absorption of fetal lung fluid finally treating TTN. The aim of our study will be to evaluate whether inhaled corticosteroids reduce respiratory distress and morbidity in late preterm and term neonates presenting with TTN.

Detailed description: The primary outcome measure will be the assessment of respiratory distress reflected by TTN clinical score in neonates presenting with TTN and treated with inhaled corticosteroids compared to placebo.

Eligibility criteria: Inclusion Criteria:

* Late preterm and term infants (post-menstrual age ≥ 34 weeks) delivered by cesarean section or vaginal delivery
* Diagnosis of TTN
* Parents signed informed consent

Exclusion Criteria:

* Meconium aspiration syndrome
* Respiratory distress syndrome
* Congenital heart disease
* Non respiratory disorders causing tachypnea

Primary outcomes:
measure: Assessment of respiratory distress
timeFrame: 48 hours
Secondary outcomes:
measure: The secondary outcome will be the assessment of morbidity associated with TTN
timeFrame: An average time period expected to be 5 days, according to the duration of hospital stay
Other outcomes:
measure: Will follow blood pressure
timeFrame: An average time period expected to be 5 days, according to the duration of hospital stay
Locations:
city: Haifa
country: Israel
facility: Bnai Zion Medical Center
Study officials:
affiliation: Bnai Zion Medical Center
name: Amir Kugelman, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Vaisbourd Y, Abu-Raya B, Zangen S, Arnon S, Riskin A, Shoris I, Elias N, Bader D, Kugelman A. Inhaled corticosteroids in transient tachypnea of the newborn: A randomized, placebo-controlled study. Pediatr Pulmonol. 2017 Aug;52(8):1043-1050. doi: 10.1002/ppul.23756. Epub 2017 Jul 3.
Clinical trial NCT05808829: The Effect of Progressive Relaxation Exercises in University Students
Official title: The Effect of Progressive Muscle Relaxation Exercise on Mental Health and Life in University Students: A Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Progressive Muscle Relaxation Exercise
Lead sponsor: Gazi University
Sponsor class: OTHER
First posted: 2023-04-11
Enrollment: 86
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The aim of this randomized controlled study is to determine the effect of progressive muscle relaxation exercise on mental health and quality of life in university students. The research was carried out with the 1st and 2nd year students of Tokat Gaziosmanpaşa University Reşadiye Vocational School Health Care Services Department Elderly Care Program. The data of the study were collected using the Introductory Information Form, Brief Symptom Inventory, and Quality of Life Scale. University students in the intervention group were given progressive muscle relaxation exercise at least 4 times a week for 6 weeks.

Detailed description: The aim of this randomized controlled parallel group single-center study is to determine the effect of progressive muscle relaxation exercise on mental health and quality of life in university students. The research was conducted online with Tokat Gaziosmanpaşa University Reşadiye Vocational School Health Care Services Department Aged Care Program 1st and 2nd grade students. The research was carried out with a total of 86 students, 43 of which were in the intervention group and 43 in the control group. The data of the study were collected using the Introductory Information Form, Brief Symptom Inventory, SF-36, Progressive Muscle Relaxation Exercise Follow-up Form. University students in the intervention group were given progressive muscle relaxation exercise at least 4 times a week for 6 weeks. No intervention was made in the control group. University students in the control group were asked to continue their daily lives. Ethics committee permission, institutional permission, scale usage permission and written consent of the participants were obtained for the research.

Eligibility criteria: Inclusion Criteria:

* Volunteering to participate in the study
* Being 18 years or older,
* Having the necessary technology to participate in the study online (Smartphone, computer, etc.)

Exclusion Criteria:

* Presence of any diagnosed musculoskeletal disease

Primary outcomes:
measure: Brief Symptom Inventory
timeFrame: 6 weeks
Secondary outcomes:
measure: The Mos 36 Item Short Form Health Survey (Sf-36)
timeFrame: 6 weeks
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Gazi University
state: Çankaya/Ankara
Study officials:
References:
Clinical trial NCT03645629: Efficacy of Lyophilized Food Extracts for Skin Prick Tests and Atopy Patch Test at Different Storage Time
Official title: Comparison of Skin Prick Tests and Atopy Patch Test Results of Lyophilized Food Extracts at Different Storage Time (0, 3 and 6 Months) After Preparation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Food Allergy
Lead sponsor: Mahidol University
Sponsor class: OTHER
First posted: 2018-08-24
Enrollment: 40
Sex: ALL
Minimum age (years): 3
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Perform skin prick test and atopy patch test of lyophilized foods (cow milk, egg white, egg yolk, wheat, soy and shrimp) stored at different time; 0, 3 and 6 months after preparation.

Then compare the results.
Primary purpose: DIAGNOSTIC

Brief summary: Comparison the result of skin prick tests and atopy patch test of lyophilized food extracts at different storage time (0, 3 and 6 months) after preparation

Detailed description: Skin prick test were performed with lyophilized food extracts (cow milk, egg white, egg yolk, wheat, soy and shrimp) at different storage time (0, 3 and 6 months) after preparation.

Atopy patch test were performed with lyophilized food extracts (cow milk, egg white, egg yolk, wheat, soy and shrimp) at different storage time (0, 3 and 6 months) after preparation

Eligibility criteria: Inclusion Criteria:

* mild to moderately severe food allergy patients
* At least positive skin test to one kind of common food (commercial extract)
* Stop antihistamine or corticosteroid (if more than 20mg/day) for at least 7 days

Exclusion Criteria:

* Dermographism
* Severe systemic disease such as autoimmune disease, immune deficiency, malignancy
* Severe dermatitis or large area involment
* pregnancy

Primary outcomes:
measure: skin test result of lyophilized foods at 6 months after preparation
timeFrame: 6 month
Secondary outcomes:
Other outcomes:
Locations:
city: Bangkok
country: Thailand
facility: Siriraj Hospital. Mahidol University
Study officials:
affiliation: Department of Pediatrics, Siriraj hospital, Mahidol University
name: Nualanong Visitsunthorn, MD
role: PRINCIPAL_INVESTIGATOR
References: